Your AI-Trained Oncology Knowledge Connection!
Dr George on Other Potential Roles for Radioligand Therapy in Prostate Cancer
Daniel J. George, MD, discusses the potential use of lutetium-177 earlier in the treatment paradigm for metastatic castration-resistant prostate cancer.
Integration of Lutetium Lu 177 Vipivotide Tetraxetan Highlights Potential of Radioligands in Prostate Cancer
Daniel J. George, MD, discusses ongoing research with radioligand therapy in prostate cancer and its potential role in novel settings and combinations.
AR Degraders, Other Novel Agents Could Expand Armamentarium in mCRPC
Sandy Srinivas, MD, discusses the therapeutic landscape of mCRPC and the need to develop novel treatment options.
Dr Srinivas on the Role of Lutetium Lu 177 Vipivotide Tetraxetan in mCRPC
Sandy Srinivas, MD, discusses the role of lutetium Lu 177 vipivotide tetraxetan for patients with metastatic castration-resistant prostate cancer.
Pirtobrutinib Improves Patient-Reported Outcomes in Relapsed/Refractory CLL/SLL
MAIC Analysis Shows PFS Favorability With Zanubrutinib vs Acalabrutinib/Venetoclax in CLL
Isa-KRd Yields Prolonged MRD Negativity vs KRd in Newly Diagnosed Myeloma
Elranatamab Triplet Yields Nearly 100% ORR in Newly Diagnosed Multiple Myeloma
